
## Johanneke E A Portielje

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4870581/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fostering Patient Choice Awareness and Presenting Treatment Options Neutrally: A Randomized Trial to Assess the Effect on Perceived Room for Involvement in Decision Making. Medical Decision Making, 2022, 42, 375-386.	2.4	2
2	Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands – A comparison of two national prospective longitudinal multi-centre cohort studies. European Journal of Cancer, 2022, 163, 189-199.	2.8	5
3	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. Clinical Cancer Research, 2022, 28, 960-971.	7.0	4
4	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. Journal of Clinical Oncology, 2022, 40, 2934-2945.	1.6	6
5	Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. Breast Cancer Research and Treatment, 2022, 193, 567-577.	2.5	10
6	Validation of the ACS NSQIP surgical risk calculator in older patients with colorectal cancer undergoing elective surgery. Journal of Geriatric Oncology, 2022, 13, 788-795.	1.0	10
7	Abstract PS6-08: The PORTRET-tool: A prediction tool for older patients with breast cancer that predicts recurrence, survival and other-cause mortality. , 2021, , .		0
8	Prediction of Other-Cause Mortality in Older Patients with Breast Cancer Using Comorbidity. Cancers, 2021, 13, 1627.	3.7	7
9	Predicting disease-related and patient-reported outcomes in older patients with breast cancer - a systematic review. Journal of Geriatric Oncology, 2021, 12, 696-704.	1.0	9
10	A Prediction Model for Severe Complications after Elective Colorectal Cancer Surgery in Patients of 70 Years and Older. Cancers, 2021, 13, 3110.	3.7	8
11	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	3.7	11
12	Can physical prehabilitation prevent complications after colorectal cancer surgery in frail older patients?. European Journal of Surgical Oncology, 2021, 47, 2830-2840.	1.0	19
13	Survival of surgical and non-surgical older patients with non-metastatic colorectal cancer: A population-based study in the Netherlands. European Journal of Surgical Oncology, 2021, 47, 3144-3150.	1.0	4
14	Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. The Lancet Healthy Longevity, 2021, 2, e704-e711.	4.6	14
15	Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison. Breast Cancer Research and Treatment, 2020, 184, 519-526.	2.5	2
16	Risk prediction models for postoperative outcomes of colorectal cancer surgery in the older population - a systematic review. Journal of Geriatric Oncology, 2020, 11, 1217-1228.	1.0	13
17	Treatment and Survival of Elderly Patients with Stage l–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Annals of Surgical Oncology, 2020, 27, 5337-5346.	1.5	9
18	Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. Journal of Geriatric Oncology, 2020, 11, 969-975.	1.0	11

#	Article	IF	CITATIONS
19	Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study. Oncologist, 2020, 25, e24-e30.	3.7	15
20	Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer. Breast Cancer Research and Treatment, 2019, 178, 637-645.	2.5	10
21	The impact of colorectal surgery on health-related quality of life in older functionally dependent patients with cancer – A longitudinal follow-up study. Journal of Geriatric Oncology, 2019, 10, 724-732.	1.0	10
22	Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer. Oncologist, 2019, 24, e467-e474.	3.7	26
23	A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer, 2019, 107, 60-67.	2.8	65
24	Evaluation and Implementation of ListeningTime: A Web-Based Preparatory Communication Tool for Elderly Patients With Cancer and Their Health Care Providers. JMIR Cancer, 2019, 5, e11556.	2.4	11
25	Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. Oncologist, 2018, 23, 982-990.	3.7	17
26	Risk stratification for surgical outcomes in older colorectal cancer patients using ISAR-HP and G8 screening tools. Journal of Geriatric Oncology, 2018, 9, 110-114.	1.0	40
27	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncology, The, 2018, 19, 1459-1467.	10.7	238
28	Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients. Cancer Management and Research, 2018, Volume 10, 3931-3935.	1.9	2
29	Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. British Journal of Cancer, 2018, 119, 517-522.	6.4	24
30	Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. British Journal of Cancer, 2018, 119, 121-129.	6.4	62
31	Prognostic Value of Geriatric 8 and Identification of Seniors at Risk for Hospitalized Patients Screening Tools for Patients With Lung Cancer. Clinical Lung Cancer, 2017, 18, 660-666.e1.	2.6	34
32	The Effect of A Geriatric Assessment on Treatment Decisions for Patients with Lung Cancer. Lung, 2017, 195, 225-231.	3.3	35
33	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Medicine, 2017, 6, 2840-2849.	2.8	41
34	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget, 2017, 8, 113531-113542.	1.8	8
35	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapyâ€free approach in HER2â€positive metastatic breast cancer: The HAT study (BOOG 2008â€2003), a Dutch Breast Cancer Research Group trial. Cancer, 2016, 122, 2961-2970.	4.1	7
36	Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as firstâ€line treatment of patients with advanced HER2â€negative gastric cancer: A multicenter phase 2 study. Cancer, 2016, 122, 1434-1443.	4.1	31

JOHANNEKE E A PORTIELJE

#	Article	IF	CITATIONS
37	A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer. Clinical Breast Cancer, 2016, 16, 379-388.	2.4	33
38	Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. European Journal of Cancer, 2016, 66, 55-66.	2.8	53
39	Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial. Oncologist, 2016, 21, 946-953.	3.7	35
40	Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. Acta Oncológica, 2016, 55, 134-139.	1.8	68
41	Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs, 2016, 34, 119-128.	2.6	30
42	Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. Journal of the National Cancer Institute, 2016, 108, djv366.	6.3	79
43	Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. Lancet Oncology, The, 2014, 15, 722-729.	10.7	81
44	Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. Journal of Geriatric Oncology, 2013, 4, 218-226.	1.0	175
45	Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial. Clinical Breast Cancer. 2011. 11. 103-113.	2.4	61
46	Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunology, Immunotherapy, 2005, 54, 37-43.	4.2	27
47	IL-12: a promising adjuvant for cancer vaccination. Cancer Immunology, Immunotherapy, 2003, 52, 133-144.	4.2	107
48	Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clinical Cancer Research, 2003, 9, 76-83.	7.0	68
49	Interleukin 12 induces activation of fibrinolysis and coagulation in humans. British Journal of Haematology, 2001, 112, 499-505.	2.5	19
50	Methionine-Enkephalin in Migraine and Tension Headache. Differences Between Classic Migraine, Common Migraine and Tension Headache, and Changes During Attacks Headache, 1990, 30, 160-164.	3.9	13